CytoReason Expands its 2019 Collaboration with Pfizer for AI Drug Development
Shots:
- CytoReason to receive a $20M equity investment while Pfizer gets the right to use CytoReason’s AI technology for drug development programs & options to license CytoReason’s platform & disease models
- Pfizer will be responsible to fund supplementary project support with a deal value of ~$110M over the 5yrs. & also gets multiple insights into R&D programs across ~20 diseases by using AI technology & has used biological models in its research for the immune system
- The research agreement and financing will allow using machine learning AI to develop high-resolution models in new therapeutic areas & develop novel treatments for immunological-mediated and immuno-oncology disorders
Ref: Pfizer | Image: Pfizer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
